APA

Wray S., Havrdova E., Snydman D. R., Arnold D. L., Cohen J. A., Coles A. J., Hartung H., Selmaj K. W., Weiner H. L., Daizadeh N., Margolin D. H., Chirieac M. C. & Compston D. A. S. (20200708). Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. : Multiple sclerosis (Houndmills, Basingstoke, England).

Chicago

Wray Sibyl, Havrdova Eva, Snydman David R, Arnold Douglas L, Cohen Jeffrey A, Coles Alasdair J, Hartung Hans-Peter, Selmaj Krzysztof W, Weiner Howard L, Daizadeh Nadia, Margolin David H, Chirieac Madalina C and Compston D Alastair S. 20200708. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. : Multiple sclerosis (Houndmills, Basingstoke, England).

Harvard

Wray S., Havrdova E., Snydman D. R., Arnold D. L., Cohen J. A., Coles A. J., Hartung H., Selmaj K. W., Weiner H. L., Daizadeh N., Margolin D. H., Chirieac M. C. and Compston D. A. S. (20200708). Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. : Multiple sclerosis (Houndmills, Basingstoke, England).

MLA

Wray Sibyl, Havrdova Eva, Snydman David R, Arnold Douglas L, Cohen Jeffrey A, Coles Alasdair J, Hartung Hans-Peter, Selmaj Krzysztof W, Weiner Howard L, Daizadeh Nadia, Margolin David H, Chirieac Madalina C and Compston D Alastair S. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. : Multiple sclerosis (Houndmills, Basingstoke, England). 20200708.